These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2420725)

  • 1. [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
    Naber KG; Adam D; Wittenberger R; Bartosik-Wich B
    Infection; 1986; 14 Suppl 1():S60-4. PubMed ID: 2420725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.
    Naber KG; Adam D; Kees F
    Drugs; 1987; 34 Suppl 1():44-50. PubMed ID: 3481328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1986; 14 Suppl 3():S203-8. PubMed ID: 3463543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
    Chen J; Chen RR; Huang HS
    J Formos Med Assoc; 2001 Aug; 100(8):548-52. PubMed ID: 11678006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of ofloxacin against complicated urinary tract infections].
    Nishio S; Yoshihara H
    Hinyokika Kiyo; 1987 Sep; 33(9):1503-7. PubMed ID: 3481217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ofloxacin versus pipemidic acid and co-trimoxazole].
    Wittenberger R
    Infection; 1986; 14 Suppl 1():S93-6. PubMed ID: 3514474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of ofloxacin (OFLX) on urinary tract infections].
    Miyata M; Inagaki N; Inada F; Yachiku S; Okamura K; Osanai H; Mizunaga M; Morikawa M
    Hinyokika Kiyo; 1987 Aug; 33(8):1303-11. PubMed ID: 3480688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].
    Naber KG; Adam D; Bauernfeind A; Hönig E
    Infection; 1986; 14 Suppl 2():S122-9. PubMed ID: 2428754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative in-vitro activity of ofloxacin.
    Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].
    Schulz W; Dörfler A
    Infection; 1986; 14 Suppl 1():S97-101. PubMed ID: 3456988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ofloxacin vs. cotrimoxazole in patients with complicated urinary tract infections.
    Vellucci A; Bernardini G; Battaglia AM; Battaglia P
    Int J Clin Pharmacol Ther Toxicol; 1987 May; 25(5):279-81. PubMed ID: 3496284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.